These results suggest that anti-CHIKV IgM provides a short period of protection during the early phase of infection for a duration of up to 10 days (varying between patients), before the mounting of an effective and strong anti-CHIKV IgG response targeting E2 glycoprotein. This evidence concerns the gene CD40LG and infection.